[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: Participants in this group will receive two doses (IM) of placebo (Adjuvant only) by 50% v/v concentration produced in RAZI institute 21 days apart followed by another dose in the form of nasal spray at day 51 (counted from day 0)", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: Participants in this group will receive two doses (IM) of RAZI recombinant spike protein vaccine 21 days apart followed by a nasal spray 51 days after the first dose (day 0).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "2;days0-21", "treatment_id": 1066, "treatment_name": "Razi cov pars", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]